Evidence map›Paper›PMID 38618500›Full record

ReviewKidney international supplements2024

Capacity for the management of kidney failure in the International Society of Nephrology Latin America region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).

Viviane Calice-Silva, Javier A Neyra, Alejandro Ferreiro Fuentes, Krissia Kamile Singer Wallbach Massai, Silvia Arruebo, Aminu K Bello, Fergus J Caskey, Sandrine Damster, Jo-Ann Donner, Vivekanand Jha and 10 more

Abstract readReview
In one paragraph

Review in Kidney international supplements, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Viviane Calice-SilvaPro-Rim Foundation, Joinville, Santa Catarina, Brazil.
Javier A NeyraDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Alejandro Ferreiro FuentesCentro de Nefrología. Facultad de Medicina. Universidad de la República, Montevideo, Uruguay.
Krissia Kamile Singer Wallbach MassaiNephrology's Intensive Care Unit, Division of Nephrology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Silvia ArrueboThe International Society of Nephrology, Brussels, Belgium.
Aminu K BelloDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Fergus J CaskeyPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Sandrine DamsterThe International Society of Nephrology, Brussels, Belgium.
Jo-Ann DonnerThe International Society of Nephrology, Brussels, Belgium.
Vivekanand JhaGeorge Institute for Global Health, University of New South Wales (UNSW), New Delhi, India.
David W JohnsonDepartment of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Adeera LevinDivision of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Charu MalikThe International Society of Nephrology, Brussels, Belgium.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Ikechi G OkpechiDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Marcello TonelliDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.
Feng YeDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Magdalena MaderoDivision of Nephrology, Department of Medicine, National Heart Institute, Mexico City, Mexico.
Carmen Tzanno MartinsRenalClass, Sao Paulo, Brazil.
Regional Board and ISN-GKHA Team Authors

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Successful management of chronic kidney disease (CKD) in Latin America (LA) continues to represent a challenge due to high disease burden and geographic disparities and difficulties in terms of capacity, accessibility, equity, and quality of kidney failure care. Although LA has experienced significant social and economic progress over the past decades, there are still important inequities in health care access. Through this third iteration of the International Society of Nephrology Global Kidney Health Atlas, the indicators regarding kidney failure care in LA are updated. Survey responses were received from 22 of 31 (71%) countries in LA representing 96.5% of its total population. Median CKD prevalence was 10.2% (interquartile range: 8.4%-12.3%), median CKD disability-adjusted life year was 753.4 days (interquartile range: 581.3-1072.5 days), and median CKD mortality was 5.5% (interquartile range: 3.2%-6.3%). Regarding dialysis modality, hemodialysis continued to be the most used therapy, whereas peritoneal dialysis reached a plateau and kidney transplantation increased steadily over the past 10 years. In 20 (91%) countries, >50% of people with kidney failure could access dialysis, and in only 2 (9%) countries, people who had access to dialysis could initiate dialysis with peritoneal dialysis. A mix of public and private systems collectively funded most aspects of kidney replacement therapy (dialysis and transplantation) with many people incurring up to 50% of out-of-pocket costs. Few LA countries had CKD/kidney replacement therapy registries, and almost no acute kidney injury registries were reported. There was large variability in the nature and extent of kidney failure care in LA mainly related to countries' funding structures and limited surveillance and management initiatives.

Indexed as

dialysiseconomic burdenhealth care accesskidney diseasekidney replacement therapyLatin America

Identifiers

PMID38618500
PMCPMC11010616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.